Bispecific antibodies in cancer therapy: Target selection and regulatory requirements
Acta Pharmaceutica Sinica B · 2023-09 · 13 (9) · 3583-3597
DOI: 10.1016/j.apsb.2023.05.023 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Pharmaceutica Sinica B, 2023-09. Verfasst von Yanze Sun und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009…. Die Arbeit wurde bisher 115-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, State Key Laboratory of Natural Medicines, National Key Research and Development Program of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
- Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
- Institute of Innovative Drug Discovery and Development, China Pharmaceutical University, Nanjing 211198, China.
Förderung
- National Natural Science Foundation of China
- State Key Laboratory of Natural Medicines
- National Key Research and Development Program of China
Zitieren
APA
Sun, Y., Yu, X., Wang, X., Yuan, K., Wang, G., Hu, L., Zhang, G., Pei, W., Wang, L., Sun, C., & Yang, P. (2023). Bispecific antibodies in cancer therapy: Target selection and regulatory requirements. Acta Pharmaceutica Sinica B, 13(9), 3583-3597. https://doi.org/10.1016/j.apsb.2023.05.023
Vancouver
Sun Y, Yu X, Wang X, Yuan K, Wang G, Hu L, et al. Bispecific antibodies in cancer therapy: Target selection and regulatory requirements. Acta Pharmaceutica Sinica B. 2023;13(9):3583-3597. doi:10.1016/j.apsb.2023.05.023
BibTeX
@article{Sun2023,
author = {Sun, Yanze and Yu, Xinmiao and Wang, Xiao and Yuan, Kai and Wang, Gefei and Hu, Lingrong and Zhang, Guoyu and Pei, Wenli and Wang, Liping and Sun, Chengliang and Yang, Peng},
title = {Bispecific antibodies in cancer therapy: Target selection and regulatory requirements},
journal = {Acta Pharmaceutica Sinica B},
year = {2023},
volume = {13},
number = {9},
pages = {3583--3597},
doi = {10.1016/j.apsb.2023.05.023}
}
EUVIMED